CAAP® – Building Companies
The OBIO® Capital Access Advisory Program (CAAP®) operates downstream from existing entrepreneurship programs and focuses on accelerating technology commercialization, working towards Series A financing and strategic partnerships. OBIO’s CAAP® creates high value deal flow for both companies and investors, culminating with a presentation at the OBIO® Investment Summit
in 2024.
What is OBIO’s CAAP®?
A competitive, 9-month structured program for health science companies starting to raise Series A financing
in Q4 2023 to 2024 timeframe.CAAP® covers three fundamental business themes:
Business strategic planning & increasing the ROI for investors
Advanced fundraising strategies & financial modeling
Closing an investment round
Benefits for CAAP® companies:
Strategic guidance from an international Steering Committee of investors, healthcare executives and business experts on how to position for a successful raise
Access to a network of advisors with expertise in technology commercialization, business development, fundraising and negotiations
Investor readiness, targeting and introductions
CAAP® culminates with a presentation at the OBIO Investment Summit (OIS):
• Present to and meet with global health sciences investors & strategics
• > $1.6B raised by Summit companies since 2018
• 200+ companies have presented at the Summit
Have a question? Contact us:
CHRISTINA YEH
Vice President, Technology Commercialization
christinayeh@obio.ca
JACK LEE
Director, Technology Commercialization
jacklee@obio.ca
CAAP® Companies 2023
CAAP® Companies 2022
CAAP® Companies 2021
CAAP® Companies 2020
CAAP® Companies 2019
